Chronic Myelogenous Leukemia News and Research

Latest Chronic Myelogenous Leukemia News and Research

Study assesses use of eMedonline to help manage patients' compliance with Gleevec

A clinical study underway at Rex Cancer Center of Wakefield will evaluate the use of telemonitoring in managing administration of Gleevec, a drug developed and manufactured by Novartis to treat chronic myeloid leukemia.

21 Apr 2010

ARIAD presents AP26113 investigational ALK inhibitor preclinical study data at AACR annual meeting

ARIAD Pharmaceuticals, Inc. today announced results of preclinical studies on its investigational anaplastic lymphoma kinase (ALK) inhibitor - AP26113 - showing potent inhibition of the target protein and of mutant forms that are resistant to the first-generation ALK inhibitor, which currently is in clinical trials in patients with cancer. ARIAD scientists presented these data today at the annual meeting of the American Association for Cancer Research (AACR) in Washington, D.C.

21 Apr 2010

CytRx' bafetinib receives EMEA COMP positive opinion for treatment of CML

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that bafetinib (formerly known as INNO-406) has received official notification from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA) that a positive opinion was made regarding the application for orphan medicinal product for the treatment of chronic myeloid leukemia (CML).

20 Apr 2010

FDA issues complete response letter regarding the NDA for OMAPRO

ChemGenex Pharmaceuticals announces that the U.S. Food and Drug Administration's Office of Oncology Drug Products has issued a complete response letter regarding the new drug application for OMAPRO for the treatment of adults with chronic myeloid leukemia who have failed prior therapy with imatinib and have the Bcr-Abl T315I mutation.

12 Apr 2010

Cepheid to launch GeneXpert Infinity-48 in Europe at 20th ECCMID

Cepheid will initiate European launch of its newest addition to the GeneXpert® family of molecular diagnostic testing systems, the GeneXpert Infinity-48, at the 20th annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Vienna, Austria. The GeneXpert Infinity-48 System is the world's first and only fully-automated, random-access system designed for management of the entire molecular testing workflow — from sample data, cartridge loading and unloading, to final reporting of test results and disposal of cartridges.

7 Apr 2010

Study: Trial vaccine eliminates residual cancer cells in CML patients

Johns Hopkins Kimmel Cancer Center researchers say preliminary studies show that a vaccine made with leukemia cells may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Imatinib mesylate (Gleevec).

3 Apr 2010

BioSante Pharmaceuticals receives FDA Orphan Drug designation for GVAX AML Vaccine

BioSante Pharmaceuticals, Inc. today announced positive GVAX AML Vaccine results and BioSante’s receipt of Orphan Drug designation from the FDA’s Office of Orphan Products Development for GVAX AML Vaccine in the treatment of acute myeloid leukemia. This Orphan Drug designation is the second GVAX cancer vaccine from BioSante to secure FDA orphan drug designation.

23 Mar 2010

ChemGenex shares falter as FDA requests more data on new leukemia drug

ChemGenex Pharmaceuticals Ltd. Shares fell most in the last 16 years to AUD$0.44 following a concern raised by the US drug regulators – US FDA. The FDA requested on Monday for more uniform clinical test data before they review and consider approval of the company’s new leukemia drug.

23 Mar 2010

FDA's ODAC voted to review T315I mutation prior to approval of OMAPRO

ChemGenex Pharmaceuticals Limited announced today that the U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee voted 7-1 that a validated test to identify the T315I mutation should be reviewed by the FDA prior to approval of OMAPRO™ (omacetaxine mepesuccinate).

23 Mar 2010

Bio-Path Holdings' liposomal Grb-2 IND receives FDA clearance to proceed into clinical trials

Bio-Path Holdings, Inc., a publicly traded biotechnology company with drug development operations in Houston, Texas, announced today that the U.S. Food and Drug Administration has allowed an IND (Investigational New Drug) for the Company’s lead cancer drug candidate liposomal Grb-2 to proceed into clinical trials.

15 Mar 2010

BeaconEquity.com: BPAX incurs net loss of $6.4M for quarter ended September 30, 2009

BeaconEquity.com announces an investment report featuring biotechnology company BioSante Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

12 Mar 2010

Positive results from BioSante Pharmaceuticals' GVAX Leukemia vaccine human clinical study

BioSante Pharmaceuticals, Inc. today announced positive results of a human clinical study that show that its GVAX Leukemia vaccine may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Gleevec (imatinib mesylate).

11 Mar 2010

Researchers discover key reason why form of leukemia progresses from chronic phase to blast crisis

Researchers have discovered a key reason why a form of leukemia progresses from its more-treatable chronic phase to a life-threatening phase called blast crisis.

5 Mar 2010

ARIAD Pharmaceuticals' investigational pan-BCR-ABL inhibitor receives FDA and EMA orphan drug designation

ARIAD Pharmaceuticals, Inc. today announced that its investigational pan-BCR-ABL inhibitor, AP24534, has been granted orphan drug designation by both the U. S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). In the U.S., the orphan designation of AP24534 is for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and in the E.U., its orphan designation is for CML and acute lymphoblastic leukemia.

2 Mar 2010

ChemGenex Pharmaceuticals' OMAPRO review: FDA reschedules ODAC meeting to 22 March, 2010

ChemGenex Pharmaceuticals Limited announced today that the U.S. Food and Drug Administration (FDA) has rescheduled the previously postponed Oncologic Drugs Advisory Committee (ODAC) meeting to 22 March 2010.

1 Mar 2010

EpiCept provides business update and fourth-quarter financial highlights

EpiCept Corporation today announced operating and financial results for the fourth quarter and year ended December 31, 2009, and provided an update on Ceplene® and several of the Company’s key product candidates.

25 Feb 2010

Novartis' Tasigna capsules granted priority review by FDA for treatment of adult patients with Ph+ CML

Novartis announced today that Tasigna® (nilotinib) 200 mg capsules has been granted priority review by the US Food and Drug Administration for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase.

19 Feb 2010

LLS increases maximum benefit for myeloma patients to $10,000

The Leukemia & Lymphoma Society (LLS) is pleased to announce that, effective Feb. 1, 2010, patients with myeloma and waldenstrom macroglobulinemia will now be able to receive up to $10,000 in support to help offset the costs of prescription drug co-pays and other insurance related expenses.

3 Feb 2010

Pfizer's new pipeline shows growth and diversity in research and development

Pfizer Inc. today provided an update to its pipeline for the first time since the close of the acquisition of Wyeth in October, 2009. The new development pipeline, composed of assets from both legacy companies, includes 133 programs from phase 1 through registration, and shows growth and increased diversity in each of the areas where the company invests in research and development.

28 Jan 2010

Health Canada approves first post-surgical treatment for patients with gastrointestinal stromal tumours

Patients with gastrointestinal stromal tumours (GIST) can now take action at an earlier stage of this rare form of cancer to reduce the risk of their disease returning following surgery. Novartis Pharmaceuticals Canada announced today that Gleevec* (imatinib mesylate) has received conditional approval by Health Canada for the adjuvant (post-surgical) treatment of adult patients who are at intermediate to high risk of disease recurrence following the surgical removal of GIST.

27 Jan 2010

Chronic Myelogenous Leukemia News and Research

Latest Chronic Myelogenous Leukemia News and Research

Study assesses use of eMedonline to help manage patients' compliance with Gleevec

ARIAD presents AP26113 investigational ALK inhibitor preclinical study data at AACR annual meeting

CytRx' bafetinib receives EMEA COMP positive opinion for treatment of CML

FDA issues complete response letter regarding the NDA for OMAPRO

Cepheid to launch GeneXpert Infinity-48 in Europe at 20th ECCMID

Study: Trial vaccine eliminates residual cancer cells in CML patients

BioSante Pharmaceuticals receives FDA Orphan Drug designation for GVAX AML Vaccine

ChemGenex shares falter as FDA requests more data on new leukemia drug

FDA's ODAC voted to review T315I mutation prior to approval of OMAPRO

Bio-Path Holdings' liposomal Grb-2 IND receives FDA clearance to proceed into clinical trials

BeaconEquity.com: BPAX incurs net loss of $6.4M for quarter ended September 30, 2009

Positive results from BioSante Pharmaceuticals' GVAX Leukemia vaccine human clinical study

Researchers discover key reason why form of leukemia progresses from chronic phase to blast crisis

ARIAD Pharmaceuticals' investigational pan-BCR-ABL inhibitor receives FDA and EMA orphan drug designation

ChemGenex Pharmaceuticals' OMAPRO review: FDA reschedules ODAC meeting to 22 March, 2010

EpiCept provides business update and fourth-quarter financial highlights

Novartis' Tasigna capsules granted priority review by FDA for treatment of adult patients with Ph+ CML

LLS increases maximum benefit for myeloma patients to $10,000

Pfizer's new pipeline shows growth and diversity in research and development

Health Canada approves first post-surgical treatment for patients with gastrointestinal stromal tumours

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Chronic Myelogenous Leukemia News and Research

Latest Chronic Myelogenous Leukemia News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in